OMBP Stock News 0.2550 05/06/2014 19:00:58 Omni Bio Pharm Inc

New Post Public Reply Private Reply Replies (0) Message Board

May 6, 2014 at 8:00 PM

Omni Bio Pharm Inc (OMBP) 0.2550 $OMBP

Omni Bio Pharmaceutical elects Dr Bruce Forrest as CDO
M2 - Fri May 02, 6:14AM CDT
Biopharmaceutical company Omni Bio Pharmaceutical (OTCQB:OMBP) disclosed on Thursday that Dr Bruce D Forrest has been named as its chief development officer.

Health Care Stocks Still Healthy Despite Higher Hedging Costs
at The Street - Fri May 02, 5:30AM CDT
Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?

Omni Bio Pharmaceutical Appoints Dr. Bruce Forrest to Chief Development Officer Role
Marketwire - Thu May 01, 8:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"

(OTCQB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the publication of final results from its pilot study of AAT in patients with recent onset Type 1 diabetes (T1D) in the Journal of Clinical Endocrinology and Metabolism.

Gallus BioPharmaceuticals partners with Omni Bio Pharmaceutical for AAT Fc fusion protein
M2 - Wed Apr 30, 3:57AM CDT
Contract manufacturing company Gallus BioPharmaceuticals said on Tuesday that it has finalised its multi-stage AAT Fc fusion protein agreement with Omni Bio Pharmaceutical (OTCQB:OMBP), a biopharmaceutical company.

Gallus Enters Cell Line Optimization and Manufacturing Agreement With Omni Bio Pharmaceutical
Marketwire - Tue Apr 29, 1:00AM CDT
Gallus BioPharmaceuticals, LLC (Gallus), a premier pure-play biologics contract development and manufacturing organization (CMO), and Omni Bio Pharmaceutical, Inc. (Omni Bio) (OTCQB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, jointly announced finalization of a multi-stage manufacturing services agreement.

Omni Bio Pharmaceutical Announces $3 Million Private Financing Plan and New Investment Banking Services Advisor
Marketwire - Thu Apr 24, 8:02AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"

, that establishes a credit facility for up to $3 million to support ongoing operations and execution of the development plan for Omni Bio's lead Fc fusion recombinant AAT molecule (Fc AAT) that is being targeted for the treatment of Type 1 diabetes, graft versus host disease and various inflammatory conditions, including chronic gout. The most immediate use of proceeds will be for cell line optimization and product manufacturing scale-up work to be performed by a contract manufacturing partner soon-to-be announced.

Omni Bio Announces Reduction in Inflammatory Myocardial Injury With Its Lead Recombinant Molecule
Marketwire - Wed Nov 20, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio"

(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced important results from new studies of its recombinant molecule, Fc-AAT.

Omni Bio Announces U.S. Patent Action for Its Recombinant Alpha-1 Antitrypsin Molecule
Marketwire - Wed Nov 06, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio"

(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced that it has received a Notice of Allowance for its first U.S. patent for the composition of matter of its lead recombinant molecule, Fc-AAT.

Omni Bio Pharmaceutical Inc appoints Sandra J. Wrobel to board
M2 - Thu Jul 18, 6:31AM CDT
Biopharmaceutical company Omni Bio Pharmaceutical Inc (OTCBB:OMBP) reported on Wednesday the election of Sandra J. Wrobel MBA to its board of directors, with effect from 15 July 2013.

Omni Bio Pharmaceutical Appoints Ms. Sandra Wrobel as New Director
Marketwire - Wed Jul 17, 3:00PM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"

(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Ms. Sandra J. Wrobel, MBA, to its Board of Directors, effective July 15, 2013.

Omni Bio Announces Support for Clinical Trial of Graft vs Host Disease
Marketwire - Wed Jul 10, 8:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"

(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced its financial support for a clinical trial of AAT for the treatment of complications following bone marrow transplantation, commonly referred to as Graft versus Host Disease ("GvHD"

.

Omni Bio Announces First Results for Its Lead Recombinant Molecule
Marketwire - Fri Mar 15, 7:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"

(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced the first disclosure of important results for its recombinant molecule, Fc-AAT.

Omni Bio Pharmaceutical Appoints Dr. Michael Kamarck as New Director
Marketwire - Wed Feb 06, 8:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio"

(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Michael E. Kamarck, Ph.D., to its Board of Directors, effective January 31, 2013.

Omni Bio Pharmaceutical CEO Provides Company Update
Marketwire - Thu Jan 31, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio"

(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today provided a company update from its new CEO, Dr. Bruce E. Schneider.

Omni Bio Pharmaceutical Appoints New CEO
Marketwire - Thu Dec 20, 7:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio"

(OTCBB: OMBP), a biopharmaceutical company focused on the development of alternative uses of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today announced the appointment of Bruce E. Schneider, PhD, as its Chief Executive Officer, effective January 1, 2013. Dr. Schneider will also become a member of the Company's board of directors. In addition to this appointment, Omni Bio announced that it has engaged Bruce D. Forrest, MD, through B D Forrest & Company, Inc., as a consultant in the areas of product and business development. Both Dr. Schneider and Dr. Forrest are former executives at Wyeth, which was acquired by Pfizer in 2009.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Betterness Expands Health Networks with $3.5M Boost

Defining a Health Revolution in the Heart of Miami Just when you think the fitness tech scene might be settling into its groove, along comes Betterness, Inc., shaking things up with another cool million in their pockets. I'm talking about their recent addition to their seed round, now sitting pretty at a robust $3.5 million. You can't ignore how they're taking a...

HiTHIUM Joins Cambridge to Boost Global Energy Storage

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Black Bayou Kicks Off Major Gas Storage Build in Louisiana

Breaking Ground on a Massive Energy Undertaking Well, folks, Black Bayou's finally breaking ground on their colossal gas storage project in Cameron Parish, Louisiana. They're not just playing around—this thing's set to be a juggernaut, with an imposing 44.4 Bcf of working gas capacity nestled right on top of the Black Bayou salt dome. Talk about marking territory, huh?...

LEOTEK's AI Tech Shaping Smarter Cities at COP31

AI-Powered Evolution in Urban Infrastructure Hang on to your hats, folks, 'cause LEOTEK is turning heads at COP31 with its AI-driven transformation of urban landscapes. As cities stretch at the seams to keep up with modern challenges, LEOTEK's got more than a few tricks up its sleeve with its trademark blend of traffic system intelligence and energy management prowess....

Dyania, NVIDIA Team Up: AI Transforming Patient Care

Revving up efficiency in healthcare usually sounds like pie-in-the-sky talk, but every now and again, an innovation comes along that really stirs the pot. Enter Dyania Health's Synapsis AI, a clinical reasoning AI, teaming with NVIDIA's robust computing infrastructure. They're setting out to make sense of massive amounts of patient data, securely tucked behind a...

LaserAway Expands to 244 Clinics Over 20 Years

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

JardogsHealth Taps Industry Titans for Growth Council

JardogsHealth: A New Chapter with Strategic Insights You've got to admire when a company rounds up a top-tier brain trust. Such is the case with JardogsHealth, the healthcare AI outfit nestled in Hillsboro, Illinois, as they align their future alongside heavyweights who’ve maneuvered through multiple industries and come out thriving. Their brand-new council includes...

Data Center Transformers on the Brink of a Boom

A Flash Look: Powering Up Data Centers Look, if you're thinking of sidestepping data center transformers as just another cog in the machine, think again. This market's set to balloon—doubling from $5.59 billion in 2026 to a jaw-dropping $10.72 billion by 2031. We're talking a chunky 13.9% CAGR. Not every bit of news grabs you by the lapels, but this one does. What’s...

Emergency Strobe Light Device Eyes Market Potential

An Idea Sparked in San Marcos This ain't your typical cocktail party chat. We're diving into a story born from necessity—where someone's trying to shave seconds off a life-or-death situation. From the busy streets of San Marcos, California, an inventor has brought a practical gem to the table: the LIFE STROBE. This gizmo is not just a bulb with a new flash pattern. It's...